HomeCompareAQNA vs ABBV

AQNA vs ABBV: Dividend Comparison 2026

AQNA yields 5.14% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AQNA wins by $8.20M in total portfolio value· pulled ahead in Year 2
10 years
AQNA
AQNA
● Live price
5.14%
Share price
$25.10
Annual div
$1.29
5Y div CAGR
64.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.31M
Annual income
$6,604,271.00
Full AQNA calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — AQNA vs ABBV

📍 AQNA pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAQNAABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AQNA + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AQNA pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AQNA
Annual income on $10K today (after 15% tax)
$436.54/yr
After 10yr DRIP, annual income (after tax)
$5,613,630.35/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, AQNA beats the other by $5,592,574.35/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AQNA + ABBV for your $10,000?

AQNA: 50%ABBV: 50%
100% ABBV50/50100% AQNA
Portfolio after 10yr
$4.20M
Annual income
$3,314,521.38/yr
Blended yield
78.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

AQNA
No analyst data
Altman Z
0.3
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AQNA buys
0
ABBV buys
0
No recent congressional trades found for AQNA or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAQNAABBV
Forward yield5.14%3.06%
Annual dividend / share$1.29$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR64.9%40.6%
Portfolio after 10y$8.31M$102.3K
Annual income after 10y$6,604,271.00$24,771.77
Total dividends collected$8.13M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AQNA vs ABBV ($10,000, DRIP)

YearAQNA PortfolioAQNA Income/yrABBV PortfolioABBV Income/yrGap
1$11,547$846.89$11,550$430.00$3.00ABBV
2← crossover$13,862$1,507.05$13,472$627.96+$390.00AQNA
3$17,621$2,788.26$15,906$926.08+$1.7KAQNA
4$24,316$5,462.16$19,071$1,382.55+$5.2KAQNA
5$37,635$11,616.48$23,302$2,095.81+$14.3KAQNA
6$67,977$27,707.94$29,150$3,237.93+$38.8KAQNA
7$149,864$77,128.19$37,536$5,121.41+$112.3KAQNA
8$422,404$262,049.04$50,079$8,338.38+$372.3KAQNA
9$1,590,253$1,138,280.96$69,753$14,065.80+$1.52MAQNA
10$8,305,842$6,604,271.00$102,337$24,771.77+$8.20MAQNA

AQNA vs ABBV: Complete Analysis 2026

AQNAStock

Algonquin Power & Utilities Corp. operates in the power and utility industries in the United States, Canada, and other regions. The company operates in two segments, Regulated Services Group and Renewable Energy Group. The company primarily owns and operates a regulated electric, water distribution and wastewater collection, and natural gas utility systems and transmission operations. As of December 31, 2023, it provided distribution services to approximately 1,256,000 customer connections in the electric (approximately 309,000 customer connections), water and wastewater (approximately 572,000 customer connections), and natural gas sectors (approximately 375,000 customer connections). The company’s electrical distribution utility systems and related transmission and generation assets are located in the states of Arkansas, California, Kansas, Missouri, Nevada, New Hampshire, and Oklahoma, and in Bermuda. Its regulated water distribution and wastewater collection utility systems are located in the states of Arizona, Arkansas, California, Illinois, Missouri, New York and Texas, and in Chile. The company’s regulated natural gas distribution utility systems located in the province of New Brunswick and the states of Georgia, Illinois, Iowa, Massachusetts, Missouri, New Hampshire and New York. It also owns and operates generating assets with a gross capacity of approximately 2.0 gigawatt (GW) and has investments in generating assets with approximately 0.3 GW of net generation capacity. The company generates and sells electrical energy, capacity, ancillary products, and renewable attributes produced by its renewable and clean power generation facilities. It has economic interests in hydroelectric, wind, solar, renewable natural gas, and thermal facilities. As of December 31, 2023, it had a combined net generating capacity attributable to the Renewable Energy Group of approximately 2.7 GW. The company was incorporated in 1988 and is headquartered in Oakville, Canada.

Full AQNA Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this AQNA vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AQNA vs SCHDAQNA vs JEPIAQNA vs OAQNA vs KOAQNA vs MAINAQNA vs JNJAQNA vs MRKAQNA vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.